Abbott India
Drug Manufacturers - Specialty & Generic · ABBOTINDIA
Large CapHealthcareMature Stable
Swati Dalal
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Abbott India is a Large Cap company in the Healthcare sector, listed on NSE as ABBOTINDIA. With a market cap of ₹58K Cr and revenue of ₹6K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. A subsidiary of a global multinational with strong emphasis on process, compliance, and a disciplined corporate structure. Its strategic mandate: Needs to shift from traditional core portfolio strengths to aggressive R&D-led specialized medical solutions to capture premium urban healthcare segments.
FAQ
What kind of company is Abbott India?
Abbott India is a Large Cap Healthcare company (ABBOTINDIA) in the Mature Stable phase with a market cap of ₹58K Cr. It is classified as Hierarchical in culture.
What is Abbott India's culture and work environment like?
Abbott India has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. A subsidiary of a global multinational with strong emphasis on process, compliance, and a disciplined corporate structure.
Who leads Abbott India?
Abbott India is led by Swati Dalal (Managing Director), a Pragmatic leader with 30 years of experience.
What are Abbott India's financials?
Abbott India reported revenue of ₹6K Cr in FY25 with a 5-year revenue CAGR of 9.3%. Operating margin: 25.7%. Market cap: ₹58K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTrusted
LifecycleMature Stable
A subsidiary of a global multinational with strong emphasis on process, compliance, and a disciplined corporate structure.
Mandate
Needs to shift from traditional core portfolio strengths to aggressive R&D-led specialized medical solutions to capture premium urban healthcare segments.
Needs to shift from traditional core portfolio strengths to aggressive R&D-led specialized medical solutions to capture premium urban healthcare segments.
Financials
Revenue FY25₹6K Cr
PAT FY25₹1K Cr
Rev CAGR 5Y9.3%
OPM25.7%
NPM22.1%
ROE33.4%
ROCE36.5%
P/E37.6
Fwd P/E33
P/B14.3
D/E4.5
Mkt Cap₹58K Cr
Promoter75.6%
Institutional7.7%
Similar Culture
Could You Lead Abbott India?
Take the Genome Benchmark →